Royalty Pharma plc (NASDAQ:RPRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Royalty Pharma plc (NASDAQ:RPRX) has been assigned an average recommendation of “Moderate Buy” from the five brokerages that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $42.00.

RPRX has been the subject of several recent research reports. The Goldman Sachs Group lifted their price target on Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. UBS Group downgraded Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 target price on the stock. in a report on Monday, June 3rd. StockNews.com cut Royalty Pharma from a “buy” rating to a “hold” rating in a report on Monday, September 9th. Finally, Morgan Stanley upped their target price on Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, July 11th.

Royalty Pharma Trading Up 0.6 %

RPRX opened at $27.72 on Monday. The company has a quick ratio of 9.35, a current ratio of 9.35 and a debt-to-equity ratio of 0.78. The firm’s 50 day moving average is $27.80 and its 200-day moving average is $28.08. The firm has a market capitalization of $16.56 billion, a P/E ratio of 20.69, a P/E/G ratio of 4.10 and a beta of 0.46. Royalty Pharma has a 52-week low of $25.20 and a 52-week high of $31.66.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.01. The business had revenue of $537.00 million for the quarter, compared to the consensus estimate of $600.83 million. Royalty Pharma had a net margin of 30.08% and a return on equity of 23.61%. During the same quarter last year, the company posted $0.85 earnings per share. Analysts expect that Royalty Pharma will post 4.04 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, September 13th. Investors of record on Friday, August 16th were paid a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a yield of 3.03%. The ex-dividend date was Friday, August 16th. Royalty Pharma’s dividend payout ratio (DPR) is presently 62.69%.

Hedge Funds Weigh In On Royalty Pharma

A number of institutional investors have recently modified their holdings of RPRX. Swedbank AB grew its holdings in Royalty Pharma by 30.6% during the second quarter. Swedbank AB now owns 10,813,470 shares of the biopharmaceutical company’s stock valued at $285,151,000 after purchasing an additional 2,533,570 shares during the period. Norges Bank purchased a new position in shares of Royalty Pharma during the fourth quarter worth about $119,740,000. New South Capital Management Inc. grew its stake in Royalty Pharma by 60.7% in the 2nd quarter. New South Capital Management Inc. now owns 2,348,977 shares of the biopharmaceutical company’s stock worth $61,943,000 after acquiring an additional 887,522 shares during the period. Homestead Advisers Corp grew its position in Royalty Pharma by 40.7% in the 1st quarter. Homestead Advisers Corp now owns 1,892,540 shares of the biopharmaceutical company’s stock worth $57,502,000 after purchasing an additional 547,000 shares during the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp grew its stake in Royalty Pharma by 10.4% in the first quarter. Mitsubishi UFJ Trust & Banking Corp now owns 1,856,998 shares of the biopharmaceutical company’s stock valued at $56,396,000 after purchasing an additional 175,261 shares in the last quarter. 54.35% of the stock is owned by institutional investors and hedge funds.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.